News | Prostate Cancer | June 15, 2017

SNMMI Announces Image of the Year

PET and Optical Imaging of Dual-Labeled PSMA Inhibitors Shows Promise for Prostate Cancer Diagnosis and Therapy 

Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may have a high clinical impact on outcomes. Researchers at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) demonstrated preclinically that dual-labeled PSMA-inhibitors based on PSMA-11 enhance preoperative staging, using PET/CT followed by fluorescence-guided surgery. The combined approach results in more accurate detection of PSMA-positive tumor lesions.

Each year, SNMMI chooses an image that exemplifies the most promising advances in the field of nuclear medicine and molecular imaging. The state-of-the-art technologies captured in these images demonstrate the capacity to improve patient care by detecting disease, aiding diagnosis, improving clinical confidence and providing a means of selecting appropriate treatments. This year, the SNMMI Image of the Year was chosen from more than 2,000 abstracts submitted to the meeting and voted on by reviewers and the society leadership.

The 2017 Image of the Year goes to a team of researchers from the German Cancer Research Center (DKFZ) and University Hospital in Heidelberg. The image clearly demonstrates how combining the advantages of 68Ga-PSMA PET and intraoperative gamma and fluorescence imaging results in better tumor identification before and during surgery.

“We are deeply honored to receive this award, and I would like to thank all team members who contributed to this interdisciplinary work,” said Ann-Christin Baranski. “As resection of lymph node metastases has considerable impact on the outcome of metastatic prostate cancer patients, the aim of our study is to improve the intraoperative accuracy of detecting PSMA-positive tumor lesions.”

“There has been a huge effort to improve care of prostate cancer patients using molecular imaging,” stated Satoshi Minoshima, M.D., Ph.D., chair of the SNMMI Scientific Program Committee and SNMMI vice president-elect. “The study presented by Ann-Christin Baranski clearly demonstrates that the combined PET imaging, gamma detection, and optical imaging can help not only pre-operative staging of the disease but also intra-operative guidance of metastatic lymph node dissection. We anticipate that such hybrid cancer detection methods will become prevalent in the near future and contribute significantly to the care and management of prostate cancer patients.” 

For more information: www.snmmi.org

Related Content

Heidelberg University Hospital Treats First Patient Using Carbon Ion Therapy With RayStation
News | Treatment Planning | August 23, 2019
Heidelberg University Hospital, Germany, has started using the RayStation treatment planning system for carbon ion...
Surging Demand for Image-guided, Stereotactic Radiation Therapy Driving Fiducial Marker Growth
News | Radiation Therapy | August 22, 2019
As fiducial markers gain traction in parallel to rising incidences of various cancer affecting lung, prostate, abdomen...
Videos | Treatment Planning | August 21, 2019
This is an example of the Mirada DLCExpert deep learning software that automatically identifies organs, segments and
Videos | Patient Positioning Radiation Therapy | August 21, 2019
This is a quick demonstration of the Varian Identify image-guided patient positioning system at the...
First Cancer Patient Treated With Accuray Radixact System With Synchrony Motion Tracking
News | Image Guided Radiation Therapy (IGRT) | August 21, 2019
Physicians at the Froedtert & the Medical College of Wisconsin (MCW) Clinical Cancer Center in Milwaukee have...
Videos | Treatment Planning | August 21, 2019
This is a lung cancer tumor radiotherapy...
Videos | Computed Tomography (CT) | August 21, 2019
This is a quick walk around of a mobile 32-slice...
Improved Imaging Technique Could Increase Chances of Prostate Cancer Survival
News | Prostate Cancer | August 20, 2019
According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their...